Table GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) [see all tables in this series...]

Part (iv) Lifetime prevalence young adults females: last survey available for each Member State (from 2000 onwards)

Notes:

 (1) Cocaine, any form. 

 (2) For Belgium National 2001 and for Metropolitan France 1995: amphetamine and ecstasy. 

 (3) For Spain: ecstasy and other designer drugs. 

 Sample sizes refer to the whole age group. Specific sample sizes by gender are not available at the moment but will be collected in the future. 

 This table aims to provide an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates, which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as a reference point for the 1993 survey. 

 In surveys with small sample sizes results should be interpreted with caution. 

 Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15–64, young adults: 15–34). In countries where age ranges are more restrictive, prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups. 

 For methods and definitions on population surveys in general, see General population surveys of drug use – methods and definitions. 

 See also 'General notes for interpreting data' on the Explanatory notes and help page. 

Sources:

 See Table GPS-0.  

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)